Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
More GEN Content From This Contributor:
- GEN Exclusives: What Is the Real Drug Development Cost for Very Small Biotech Companies?
- GEN Exclusives: Guiding Drug Development: A Pharmacoeconomic Look
- GEN Exclusives: The Promise of Combination Therapies
- GEN Exclusives: Big Pharma Issues and Strategy in a Single Visual
- GEN Exclusives: Why Big Pharma Needs Blockbusters
- GEN Exclusives: Why Is Everybody Picking on Sovaldi?